Skip to content

Effect of Stellate Ganglion Block on Blood Flow in the Cannulated Radial Artery

Effect of Stellate Ganglion Block on Blood Flow in the Cannulated Radial Artery in Septic Shock Patients on Vasopressors, A Feasibility Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03042663
Enrollment
34
Registered
2017-02-03
Start date
2016-03-01
Completion date
2017-10-04
Last updated
2017-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radial Artery Cannulation, Stellate Ganglion Block

Keywords

stellate ganglion block, arterial cannula, ischemia, septic shock

Brief summary

To evaluate the value of US-guided Stellate ganglion block for improving radial arterial blood flow and peripheral perfusion in Septic shock patients on vasopressor support with an indwelling radial arterial cannula, which can result in reduced incidence premature failure of the catheter (due to vasospasm or thrombosis) and incidence of ischemic complications in the cannulated arm.

Detailed description

Radial artery cannulation is a well-established procedure in the ICU, especially in critically ill hemodynamically unstable patients. The first description of arterial cannulation in humans dates back to 1856, when the blood pressure was measured int the femoral artery. It can be used for continuous blood pressure monitoring, obtaining func¬tional hemodynamic parameters derived from the arterial waveform, to predict the physiologic response to fluid resuscitation and also for blood sampling. The most common complications for the procedure are temporary radial artery occlusion (19.7%), in addition to hematoma (14.4%), infection at the arterial site (0.72%), hemorrhage (0.53%) or bacteremia (0.13%), pseudoaneurysm (0.09%) and finally ischemic damage (0.09%). Larger catheter diameter, presence of vasospasm, female sex (probably related to smaller vessel diameter) increase the risk of ischemic complications. Inadequate experience (high number of attempts, multiple arterial sticks and hematoma formation) can also increase the complication rate. In a recent study by Numaguchi et al, they found that radial artery cannulation decreases the distal arterial blood flow measured by power Doppler ultrasound. In another study by Kim et al, they found that after radial artery cannulation ulnar artery diameters were significantly increased (compensatory) and radial artery diameters were decreased after cannulation compared with pre-cannulation values, then returned to pre-cannulation values 5 min after cannulation. They detected radial artery vasospasm in 12 patients with 20-G cannulas used (31.5%) and in 2 patients with 22-G cannulas used (5.3%) (p \< 0.05), which was observed immediately after cannulation, and had mostly disappeared after 5 min. There was no data regarding the follow up of the patients afterwards. In both studies the subjects were not critically ill patients (and not on vasopressors). Peripheral limb ischemia in ICU patients can be the result of iatrogenic injury, thrombotic complications or hypoperfusion related to the underlying disease state. The patients at greatest risk for acute ischemia are those with underlying peripheral artery disease (PAD), but limb ischemia can also be the consequence of embolism, injury, dissection, or severe vasoconstriction, even in the absence of preexisting occlusive disease. Repeated arterial punctures may result in extensive hematoma formation and arterial spasm, The thick muscular coat and abundance of alpha adrenoreceptors make it prone to develop spasm when traumatized. Attempts to control bleeding following cannulation through local hemostasis only complicate matters. While, normally, the likelihood of serious ischemia is minimized by the presence of the palmar arterial arch. The use of vasopressors especially nor-epinephrine with its potent α1-adrenergic receptor agonist activity can aggravate the condition more. We didn't find in the literature any reliable data regarding the effect of using vasopressors (particularly nor-epinephrine) in any dosage on the incidence of peripheral arterial vasospasm or ischemic complications following arterial cannulation. But there were mixed case reports linking both or one of them: high dose vasopressors and arterial cannulation, to ischemic complications. Such as developing peripheral gangrene after starting high dose vasopressors, or developing complex regional pain syndrome (CRPS) following radial artery cannulation. It is believed that blocking the Stellate ganglion with Local anesthetics can interfere with the sympathetic out flow to the upper limb resulting in abolishing its vasoconstrictor action on the arteries thus decreasing arterial spasm and promoting better blood flow in the peripheral circulation.

Interventions

PROCEDUREUSG stellate ganglion block

After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.

Sponsors

Eslam Ayman Mohamed Shawki
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The study will recruit septic shock patients with hemodynamic instability on vasopressor support and on direct arterial blood pressure monitoring through a radial arterial cannula that is not older than 12 hours.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age range of 18-80 years. * Septic shock patients on vasopressor support (Nor-epinephrine or epinephrine). * Presence of an indication for an arterial cannula.

Exclusion criteria

* Coagulopathies (with prothrombin concentration less than 60% or international normalized ratio INR more than 1.5) * In-ability to postpone anti-coagulation medications. * Infection or injury or a lesion at the block site. * Suspected cervical vertebral column injury necessitating using a neck collar. * Bradycardia with heart rate less than 60 beat per minute. * A compromised lung on the contralateral side of the arterial cannula (Pneumothorax, hemothorax or Pneumonectomy). * Recent cardiac insult (cardiogenic shock) (Due to blockage of the sympathetic cardiac accelerator fibers by the block). * Traumatic vascular injuries or operative interventions (Surgical harvesting) involving arteries of the upper limb on either side. * Peripheral vascular disease, atherosclerosis, atrial fibrillation, previous history of ischemic injuries, hypercoagulable syndromes.

Design outcomes

Primary

MeasureTime frameDescription
change in Perfusion Index (PI)After 30 minutes then every hour for 6 hourschange in Perfusion Index (PI) in the cannulated limb before and after the Stellate ganglion block.

Secondary

MeasureTime frameDescription
Perfusion Index (PI) after Stellate ganglion block6 hoursPerfusion Index (PI) values bilaterally after Stellate ganglion block in the cannulated side.
Doppler Blood flow values after cannulation3 hoursDoppler Blood flow values in the both Radial arteries after cannulation of one of them.
Doppler Blood flow after Stellate ganglion block6 hoursDoppler Blood flow values in the both Radial arteries after Stellate ganglion block in the cannulated side.
Perfusion Index (PI) after cannulation3 hoursPerfusion Index (PI) values bilaterally after radial arterial cannulation
Incidence of complications6 hoursIncidence of complications related to the Stellate ganglion block (Hematoma, Intravascular injection, Intrathecal injection, pneumothorax).
Incidence of ischemic complications6 hoursIncidence of ischemic complications related to the arterial cannula (Unilateral) or Vasopressors and general condition of the patient (Bilateral) (changes in the form of either color changes or definite gangrene).
Vasopressor drug dose6 hoursDoses of vasopressor drugs used.

Countries

Egypt

Contacts

Primary ContactEslam A Shawki, M.D.
eslam.ayman@kasralainy.edu.eg+201225771017

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026